Cargando…
First-In-Human Trials of GamTBvac, a Recombinant Subunit Tuberculosis Vaccine Candidate: Safety and Immunogenicity Assessment
Tuberculosis is known to be the biggest global health problem, causing the most deaths by a single infectious agent. Vaccine-development efforts are extremely important. This paper represents the results of the first-in-human trial of recombinant subunit tuberculosis vaccine GamTBvac in a Phase I st...
Autores principales: | Vasina, Daria V., Kleymenov, Denis A., Manuylov, Victor A., Mazunina, Elena P., Koptev, Egor Yu., Tukhovskaya, Elena A., Murashev, Arkady N., Gintsburg, Alexander L., Gushchin, Vladimir A., Tkachuk, Artem P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963980/ https://www.ncbi.nlm.nih.gov/pubmed/31683812 http://dx.doi.org/10.3390/vaccines7040166 |
Ejemplares similares
-
Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study
por: Tkachuk, Artem P., et al.
Publicado: (2020) -
Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and guinea pig TB models
por: Tkachuk, A. P., et al.
Publicado: (2017) -
Avidity of IgG to SARS-CoV-2 RBD as a Prognostic Factor for the Severity of COVID-19 Reinfection
por: Manuylov, Victor, et al.
Publicado: (2022) -
Impact of Aerosol Dust on xMAP Multiplex Detection of Different Class Pathogens
por: Kleymenov, Denis A., et al.
Publicado: (2017) -
TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development
por: Kaufmann, Stefan H. E., et al.
Publicado: (2017)